CPI-203 1 mg | ≥99% LKT Laboratories, Inc. Triazolothienodiazepine, JQ-1 derivative; BRD inhibitor. More Information Supplier Page × CPI-203
(+)-JQ-1 25 mg | ≥99% LKT Laboratories, Inc. Triazolothienodiazepine; BRD inhibitor. More Information Supplier Page × (+)-JQ-1
(+)-JQ-1 5 mg | ≥99% LKT Laboratories, Inc. Triazolothienodiazepine; BRD inhibitor. More Information Supplier Page × (+)-JQ-1
(+)-JQ-1 1 mg | ≥99% LKT Laboratories, Inc. Triazolothienodiazepine; BRD inhibitor. More Information Supplier Page × (+)-JQ-1
S-(−)-Sulpiride 1 g | ≥99% LKT Laboratories, Inc. GHB agonist, D2/3 antagonist. More Information Supplier Page × S-(−)-Sulpiride
Dapoxetine Hydrochloride 100 mg | ≥99% LKT Laboratories, Inc. SERT inhibitor, potential voltage-gated K+ channel blocker. More Information Supplier Page × Dapoxetine Hydrochloride
Dapoxetine Hydrochloride 50 mg | ≥99% LKT Laboratories, Inc. SERT inhibitor, potential voltage-gated K+ channel blocker. More Information Supplier Page × Dapoxetine Hydrochloride
Dapoxetine Hydrochloride 10 mg | ≥99% LKT Laboratories, Inc. SERT inhibitor, potential voltage-gated K+ channel blocker. More Information Supplier Page × Dapoxetine Hydrochloride
